Editorial
Copyright ©The Author(s) 2020.
World J Clin Oncol. Dec 24, 2020; 11(12): 983-989
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.983
Table 1 Prospective clinical trials in oligometastatic disease
Trial
Ref.
Design
Population
Number of lesions
Local treatment
PFS
OS
SABR-COMETPalma et al[11]Phase II, n = 99≤ 5 locations; different tumour types (lung cancer; n = 18)1-5SABR12 mo vs 6 mo, (P = 0.0012)41 mo vs 28 mo, (P = 0.09)
Iyengar et al[12]Phase II, n = 29Lung cancer patients treated with induction chemotherapy followed by standard maintenance treatment (+/-SBRT) 1-5SABR9.7 mo vs 3.5 mo, (P = 0.01)Not reported
“Oligomez”Gomez et al[13]Phase II, n = 49Lung cancer patients treated with induction chemotherapy followed by standard maintenance treatment (+/-SBRT)1-3XRT or Surgery14.2 mo vs 4.4 mo, (P = 0.022)41.2 mo vs 17 mo, (P = 0.017)
SINDASWang e et al[14]Phase III, n = 133Front line treatment for EGFR + NSCLC patients with ≤ 5 metastases. EGFR-TKI vs SBRT + EGFR-TKI1-5SBRT20.2 mo vs 12.5 mo, (P < 0.01)25.5 mo vs 17.4 mo, (P < 0.01)